{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Renal+Diseases&page=28",
    "query": {
      "condition": "Chronic Renal Diseases",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 1881,
    "total_pages": 189,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Renal+Diseases&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Renal+Diseases&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T00:35:05.717Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02579096",
      "title": "CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Gout",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "allopurinol capsule, 100-800 mg by mouth once daily",
          "type": "DRUG"
        },
        {
          "name": "febuxostat tablet 40-120 mg by mouth once daily",
          "type": "DRUG"
        },
        {
          "name": "Placebo, vehicle control (febuxostat-shaped)",
          "type": "DRUG"
        },
        {
          "name": "Placebo, vehicle control (allopurinol-shaped)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 950,
      "start_date": "2017-03-06",
      "completion_date": "2021-04-15",
      "has_results": true,
      "last_update_posted_date": "2024-03-29",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 23,
      "location_summary": "Loma Linda, California • San Diego, California • San Francisco, California + 19 more",
      "locations": [
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Hines",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579096"
    },
    {
      "nct_id": "NCT01604577",
      "title": "Targeting Social Determinants to Improve Chronic Kidney Disease Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "interactive educational intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 273,
      "start_date": "2012-05",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2014-07-29",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01604577"
    },
    {
      "nct_id": "NCT05614115",
      "title": "Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End-stage Kidney Disease",
        "Kidney Disease, Chronic",
        "Dialysis",
        "Diabetic",
        "Non-diabetic",
        "Kidney Dysfunction",
        "Kidney Failure",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2023-03-21",
      "completion_date": "2025-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-12",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614115"
    },
    {
      "nct_id": "NCT06927024",
      "title": "Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Active taVNS",
          "type": "DEVICE"
        },
        {
          "name": "Sham taVNS",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-10-15",
      "completion_date": "2029-01-31",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06927024"
    },
    {
      "nct_id": "NCT01399580",
      "title": "A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Diabetic Nephropathy"
      ],
      "interventions": [
        {
          "name": "Atrasentan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2011-08",
      "completion_date": "2012-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-25",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Tempe, Arizona • Azusa, California + 23 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Azusa",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399580"
    },
    {
      "nct_id": "NCT05381961",
      "title": "Observational Study of BIS in Hemodialysis Patients",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Failure, Chronic",
        "Renal Failure Chronic",
        "Hemodialysis"
      ],
      "interventions": [
        {
          "name": "Bioimpedance spectroscopy (BIS) measurement, SOZO device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ImpediMed Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2022-04-04",
      "completion_date": "2023-09",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 2,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05381961"
    },
    {
      "nct_id": "NCT01026363",
      "title": "hCAP18 Levels and Vitamin D Deficiency in Chronic Kidney Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Vitamin D Deficiency"
      ],
      "interventions": [
        {
          "name": "Ergocalciferol",
          "type": "DRUG"
        },
        {
          "name": "Calcitriol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-12",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-09-23",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 1,
      "location_summary": "Cambridge, Massachusetts",
      "locations": [
        {
          "city": "Cambridge",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01026363"
    },
    {
      "nct_id": "NCT00921687",
      "title": "Chronic Kidney Disease (CKD) Guideline Adherence - A Quality Improvement Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Renal Insufficiency"
      ],
      "interventions": [
        {
          "name": "Education only",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Multifactorial intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Louis Stokes VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 781,
      "start_date": "2009-07",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2013-05-27",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00921687"
    },
    {
      "nct_id": "NCT05001009",
      "title": "Goals of Care Conversations Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Seriously Ill Patients",
        "Cancer",
        "Heart Failure",
        "Interstitial Lung Disease",
        "Chronic Obstructive Pulmonary Disease",
        "End-stage Renal Disease",
        "End-stage Liver Disease",
        "Dementia"
      ],
      "interventions": [
        {
          "name": "Clinician Implementation Strategy Stage 1: low intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinician Implementation Strategy Stage 2: high intensity clinician training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Low patient engagement",
          "type": "BEHAVIORAL"
        },
        {
          "name": "High patient engagement",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2859,
      "start_date": "2022-09-13",
      "completion_date": "2025-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • West Los Angeles, California • Aurora, Colorado",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "West Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05001009"
    },
    {
      "nct_id": "NCT01460134",
      "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma",
        "Marginal Zone B Cell Lymphoma)",
        "Any T-cell Malignancy",
        "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma",
        "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer",
        "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)",
        "Burkett's Lymphoma",
        "Primary Lymphoma of the Central Nervous System"
      ],
      "interventions": [
        {
          "name": "CDX-1127",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2011-10",
      "completion_date": "2017-10-16",
      "has_results": false,
      "last_update_posted_date": "2018-01-31",
      "last_synced_at": "2026-10-17T00:35:05.717Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01460134"
    }
  ]
}